The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Abbvie; Accutar Biotech; Allorion Therapeutics; Araxes Pharma; AstraZeneca; Bayer; Biocartis; Biocartis; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Lilly; LOXO; Merrimack; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche/Genentech; Sanofi; SFJ Pharmaceuticals Group; Silicon Therapeutics; Syndax; Takeda; Transcenta; Voronoi Health Analytics
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology; Revolution Medicines; Takeda
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
 
Mengzhao Wang
No Relationships to Disclose
 
D. Ross Camidge
Honoraria - Abbvie; Amgen Astellas BioPharma; Anheart Therapeutics; Apollomics; AstraZeneca; BeiGene; bio-thera; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevation Oncology; EMD Serono; GlaxoSmithKline; Helsinn Therapeutics; Hengrui Pharmaceutical; Janssen; Kestrel Labs; Lilly; Mersana; Nuvalent, Inc.; OnKure; Pfizer; Puma Biotechnology; QiLu Pharmaceutical; Ribon Therapeutics; Roche; Sanofi; Seagen; takeda; Turning Point Therapeutics
Research Funding - Inivata (Inst)
 
Paul Mitchell
Honoraria - AstraZeneca; MSD; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; Boehringer Ingelheim; MSD; PUMA Biotechnology; Roche; Specialised Therapeutics
 
Jian Fang
No Relationships to Disclose
 
Weiqi Nian
No Relationships to Disclose
 
Chao-Hua Chiu
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma (Inst)
 
Jianying Zhou
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Wu-Chou Su
Consulting or Advisory Role - Bayer Schering Pharma; Lilly; Merck; MSD Oncology
 
Tsung-Ying Yang
No Relationships to Disclose
 
Viola Weijia Zhu
Employment - Nuvalent, Inc.
Stock and Other Ownership Interests - Nuvalent, Inc.; TP Therapeutics; TP Therapeutics (I)
Honoraria - AstraZeneca; BeiGene; Blueprint Medicines; Roche/Genentech; Takeda; Xcovery
Consulting or Advisory Role - AstraZeneca; BeiGene; Roche/Genentech; Takeda; TP Therapeutics; Xcovery
Speakers' Bureau - AstraZeneca; Blueprint Medicines; Roche/Genentech; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Roche/Genentech; Takeda; TP Therapeutics
 
Michael Millward
Consulting or Advisory Role - Amgen; BeiGene; Guardant Health; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda; The Limbic
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Albion Laboratories (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Apollomics (Inst); AstraZeneca (Inst); AtriCure (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Dizal Pharma (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genfleet Therapeutics (Inst); GlaxoSmithKline (Inst); InventisBio (Inst); Lilly (Inst); Maxinovel (Inst); Novartis (Inst); Relay Therapeutics (Inst); Roche (Inst); Takeda (Inst); Therapim (Inst); Turning Point Therapeutics (Inst); Vivace Therapeutics (Inst); Vivace Therapeutics (Inst)
 
Yun Fan
No Relationships to Disclose
 
Wen-Tsung Huang
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Liyan Jiang
No Relationships to Disclose
 
Daniel Brungs
No Relationships to Disclose
 
Li Zheng
No Relationships to Disclose
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Daiichi Sankyo (Inst); G1 Therapeutics; GlaxoSmithKline (Inst); Hansoh; Incyte; Janssen (Inst); Lilly; Merck Serono; Merck Serono (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; Novartis (Inst); Ono Pharmaceutical; Pfizer; Takeda; Takeda (Inst); Yuhan
Travel, Accommodations, Expenses - Pfizer